REMfresh®
REMfresh®, licence 80109545: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Other names
- REMfresh® 5 mg, REMfresh® CRA-melatoninTM
- Licence holder
- Physician's Seal LLC
- NPN or DIN-HM
- 80109545
- Status
- Active licence
- Licence date
- 27 April 2021
- Revision date
- Not provided
- Form
- Comprimé, enrobé par pellicule, libération prolongée
- Route of administration
- Orale
- Application type
- Générale (non traditionelle)
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| N-acétyl-5-méthoxytryptamine Source : Mélatonine | 5.0 mg | Not calculated |
Non-medicinal ingredients
Stéarate de magnésium, Poly(éthylène glycol), Dioxyde de silicium, Poly(sorbate) 80, Silicate de magnésium, Amidon de maïs, Monohydrate de glucose, Pigments nacrés à base de mica, Carboxyméthylcellulose, Laque d'aluminium bleu FD&C n° 1, Dioxyde de titane, Glycérine, Poly(alcool vinylique), Hydroxypropyl méthylcellulose, Cellulose microcristalline, Acide citrique
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19.0 Année(s) | minimum: 1.0 Comprimé ; maximum: 2.0 Comprimé | 1.0 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Helps re-set the body's sleep-wake cycle (aspect of the circadian rhythm). Helps re-set the body's sleep-wake cycle (aspect of the circadian rhythm) and increase the total sleep time (aspect of sleep quality) in people suffering from sleep restriction or altered sleep schedule (e.g. shift work and jet lag). Helps to speed up/ reduce the time it takes to fall asleep (sleep onset latency aspect of sleep quality) in people who fall asleep slowly/ with delayed sleep phase disorder.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80109545
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.